Anthem Biosciences Limited has informed the Exchange about Investor Presentation
ANTHEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Anthem Biosciences reported strong Q4FY26 and FY26 results. Q4FY26 revenue was Rs 6,109 Mn (up 26% YoY), the highest ever quarterly revenue. EBITDA grew 52% YoY to Rs 3,184 Mn with margins expanding to 48.1% from 42.1% a year ago. Full year FY26 revenue was Rs 21,243 Mn (up 15% YoY) with EBITDA at Rs 9,896 Mn (up 31% YoY) and PAT at Rs 5,918 Mn (up 31% YoY). EBITDA margins improved by 420 bps to 43.4% for FY26. The company operates in two segments: CRDMO (Contract Research and Manufacturing) contributing 83% of revenue and Specialty Ingredients at 16%. Net cash position strengthened to Rs 13,743 Mn. The company is building a new greenfield facility at Harohalli with Rs 12,000 Mn Phase I investment. Management cited prudent cost management as key to margin expansion while delivering this growth.
The stock shows strong operational performance with significant margin expansion and robust cash generation. The consistent beat in profitability metrics and clear focus on cost efficiency could be positive for shareholder returns and the stock price.